These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer's disease: An in silico and in vitro study. Mateev E; Kondeva-Burdina M; Georgieva M; Zlatkov A J Mol Graph Model; 2023 Jul; 122():108471. PubMed ID: 37087882 [TBL] [Abstract][Full Text] [Related]
43. Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer's Disease. Kaniakova M; Nepovimova E; Kleteckova L; Skrenkova K; Holubova K; Chrienova Z; Hepnarova V; Kucera T; Kobrlova T; Vales K; Korabecny J; Soukup O; Horak M Curr Alzheimer Res; 2019; 16(9):821-833. PubMed ID: 30819076 [TBL] [Abstract][Full Text] [Related]
44. Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease. Sivaraman B; Raji V; Velmurugan BA; Natarajan R CNS Neurol Disord Drug Targets; 2022; 21(5):427-449. PubMed ID: 34602041 [TBL] [Abstract][Full Text] [Related]
45. In silico and in vitro anti-AChE activity investigations of constituents from Mytragyna speciosa for Alzheimer's disease treatment. Innok W; Hiranrat A; Chana N; Rungrotmongkol T; Kongsune P J Comput Aided Mol Des; 2021 Mar; 35(3):325-336. PubMed ID: 33439402 [TBL] [Abstract][Full Text] [Related]
46. Combining in silico and in vitro approaches to evaluate the acetylcholinesterase inhibitory profile of some commercially available flavonoids in the management of Alzheimer's disease. Kuppusamy A; Arumugam M; George S Int J Biol Macromol; 2017 Feb; 95():199-203. PubMed ID: 27871793 [TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease. Xiao G; Li Y; Qiang X; Xu R; Zheng Y; Cao Z; Luo L; Yang X; Sang Z; Su F; Deng Y Bioorg Med Chem; 2017 Feb; 25(3):1030-1041. PubMed ID: 28011206 [TBL] [Abstract][Full Text] [Related]
48. Probing the intermolecular interactions, binding affinity, charge density distribution and dynamics of silibinin in dual targets AChE and BACE1: QTAIM and molecular dynamics perspective. Saravanan K; Sugarthi S; Suganya S; Kumaradhas P J Biomol Struct Dyn; 2022; 40(23):12880-12894. PubMed ID: 34637680 [TBL] [Abstract][Full Text] [Related]
49. De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents. Pandey S; Singh BK Curr Comput Aided Drug Des; 2020; 16(1):54-72. PubMed ID: 30827255 [TBL] [Abstract][Full Text] [Related]
50. Oxime-dipeptides as anticholinesterase, reactivator of phosphonylated-serine of AChE catalytic triad: probing the mechanistic insight by MM-GBSA, dynamics simulations and DFT analysis. Chadha N; Tiwari AK; Kumar V; Lal S; Milton MD; Mishra AK J Biomol Struct Dyn; 2015; 33(5):978-90. PubMed ID: 24805972 [TBL] [Abstract][Full Text] [Related]
52. Molecular evaluation of herbal compounds as potent inhibitors of acetylcholinesterase for the treatment of Alzheimer's disease. Chen YX; Li GZ; Zhang B; Xia ZY; Zhang M Mol Med Rep; 2016 Jul; 14(1):446-52. PubMed ID: 27176468 [TBL] [Abstract][Full Text] [Related]
53. New azole-derived hemiaminal ethers as promising acetylcholinesterase inhibitors: synthesis, X-ray structures, Nisar M; Gondal HY; Cheema ZM; Yousaf S; Nadeem H J Biomol Struct Dyn; 2023; 41(24):15535-15548. PubMed ID: 37021341 [TBL] [Abstract][Full Text] [Related]
54. Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors. Deb PK; Sharma A; Piplani P; Akkinepally RR Mol Divers; 2012 Nov; 16(4):803-23. PubMed ID: 22996404 [TBL] [Abstract][Full Text] [Related]
55. Exploring the interaction mechanism between potential inhibitor and multi-target Mur enzymes of mycobacterium tuberculosis using molecular docking, molecular dynamics simulation, principal component analysis, free energy landscape, dynamic cross-correlation matrices, vector movements, and binding free energy calculation. Kumari M; Singh R; Subbarao N J Biomol Struct Dyn; 2022; 40(24):13497-13526. PubMed ID: 34662260 [TBL] [Abstract][Full Text] [Related]
56. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease. Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948 [TBL] [Abstract][Full Text] [Related]
57. The impact of some phenolic compounds on serum acetylcholinesterase: kinetic analysis of an enzyme/inhibitor interaction and molecular docking study. Işık M; Beydemir Ş J Biomol Struct Dyn; 2021 Oct; 39(17):6515-6523. PubMed ID: 32746727 [TBL] [Abstract][Full Text] [Related]
58. Molecular Docking and Dynamic Simulation Studies of Terpenoids of I. wightii (Bentham) H. Hara against Acetylcholinesterase and Histone Deacetylase3 Receptors. Ramnath MG; Thirugnanasampandan R; NagaSundaram N; Bhuvaneswari G Curr Comput Aided Drug Des; 2018; 14(3):234-245. PubMed ID: 29564983 [TBL] [Abstract][Full Text] [Related]
59. Virtual Screening and Hit Selection of Natural Compounds as Acetylcholinesterase Inhibitors. Atanasova M; Dimitrov I; Ivanov S; Georgiev B; Berkov S; Zheleva-Dimitrova D; Doytchinova I Molecules; 2022 May; 27(10):. PubMed ID: 35630613 [TBL] [Abstract][Full Text] [Related]
60. Effect of Salvia miltiorrhiza on acetylcholinesterase: Enzyme kinetics and interaction mechanism merging with molecular docking analysis. Tang H; Song P; Li J; Zhao D Int J Biol Macromol; 2019 Aug; 135():303-313. PubMed ID: 31128195 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]